DURVALUMAB , Ifinatamab Deruxtecan, MK-6070
MK-6070-002
Phase 2 small_molecule active
Quick answer
DURVALUMAB , Ifinatamab Deruxtecan, MK-6070 for Small cell lung cancer is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Small cell lung cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active